Taft Stettinius & Hollister LLP | USA | 6 Mar 2023
The Novartis v. HEC patent case on the drug fingolimod is pending in the Supreme Court and has a unique history. Therefore, a group of retired…
Taft Stettinius & Hollister LLP | USA | 10 Aug 2021
On Aug. 5, the Federal Circuit reaffirmed its 2-1 prior decision that Teva’s sales of carvedilol, a cardiovascular drug, induced infringement of…
Taft Stettinius & Hollister LLP | USA | 11 Jun 2021
For a patent owner wishing to stop infringement, there have historically been two options in reaching out to an infringer in another state. The first…
Taft Stettinius & Hollister LLP | USA | 27 Jan 2021
Over the years on Taft’s Privacy and Data Security Insights, we have written on the risk of data breaches and the specific impact on privacy, or the…
Taft Stettinius & Hollister LLP | USA | 11 Aug 2020
The Inter Partes Review (IPR) statute is clear - challenges to the validity of a patent’s claims through the IPR process are limited to those based…
Taft Stettinius & Hollister LLP | USA | 6 May 2020
The United States Patent and Trademark Office (USPTO) has launched “Patents 4 Partnerships” to provide a user-friendly, searchable repository of…
Taft Stettinius & Hollister LLP | USA | 29 Apr 2020
On April 28, 2020, the United States Patent & Trademark Office (USPTO) extended fee relief for certain delays in patent-related filings that can be…
Taft Stettinius & Hollister LLP | USA | 22 Apr 2020
The U.S. Supreme Court (Supreme Court) ruled on April 20, 2020, that a patent owner may not appeal the decision of the U.S. Patent Trial and Appeal…
Taft Stettinius & Hollister LLP | USA | 8 Apr 2020
As we reported in March, the CARES Act gives the Director of the United States Patent and Trademark Office (USPTO) the authority to extend deadlines…